The beneficial effect of complex I {[Ru(bpy)2(NO)SO3](PF6)} in gout depends on the activation of the cGMP/PKG/ATP-sensitive potassium channel signaling pathway and inhibition of NF-κB activation. This evidence concerns the gene PRKG1 and gout.